JC10 Rec'd PCT/PTQ 23 MAR 2005

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

ATTORNEY'S DOCKET NUMBER 2376.0010000/SRL/TAC

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

CON	ACEKIAIIAO A SUBIVIISSIO	To be assigned \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \								
INTERNA	PCT/DE2003/ ,03165	international filing date 23 September 2003	PRIORITY DATE CLAMED 24 September 2002							
TITLE OF INVENTION Inhibition Of Protein Kinase C Alpha For Treatment Of Diabetes Mellitus And Cardiovascular Diseases										
APPLICANT(S) FOR DO/EO/US Jan MENNE and Hermann HALLER										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:										
1. X	This is a FIRST submission of items co	oncerning a submission under 35 U.S.C. 371	ı.							
2.	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.									
3. X	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.									
4. X	The US has been elected (Article 31).									
5. X	A copy of the International Application	n as filed (35 U.S.C. 371(c)(2))								
	a. is attached hereto (required only if not communicated by the International Bureau).									
	b. X has been communicated by the International Bureau.									
	c. is not required, as the applic	cation was filed in the United States Receivi	ing Office (RO/US).							
6. X	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).									
	a. X is attached hereto.									
	b. has been previously submit	itted under 35 U.S.C. 154(d)(4).								
7.	Amendments to the claims of the Inte	ernational Application under PCT Article 19 ((35 U.S.C. 371(c)(3))							
	a. are attached hereto (requir	ired only if not communicated by the Internal	tional Bureau).							
	b. have been communicated	by the International Bureau.								
	c. have not been made; howe	ever, the time limit for making such amendr	nents has NOT expired.							
	d. have not been made and v	will not be made.								
8.	An English language translation of th	ne amendments to the claims under PCT Art	ticle 19 (35 U.S.C. 371(c)(3)).							
9.	An oath or declaration of the inventor	(s) (35 U.S.C. 371(c)(4)).								
10.	An English language translation of the Article 36 (35 U.S.C. 371(c)(5)).	e annexes of the International Preliminary E	xamination Report under PCT							
Items	s 11 to 20 below concern document(s	i) or information included:								
11.	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.								
12.	An assignment document for recording	ng. A separate cover sheet in compliance wi	th 37 CFR 3.28 and 3.31 is included.							
13. X	A preliminary amendment.									
14. X	An Application Data Sheet under 37 C	CFR 1.76.								
15.	A substitute specification.									
16. 🔲	A power of attorney and/or change of	address letter.								
17. 🗌	A computer-readable form of the sequ	uence listing in accordance with PCT Rule 1	3ter.2 and 37 CFR 1.821- 1.825.							
18.	A second copy of the published Intern	national Application under 35 U.S.C. 154(d)((4).							
19.	A second copy of the English languag	ge translation of the international application	under 35 U.S.C. 154(d)(4).							
20. X	Other items or information: copy of J	International Search Report; and Copy	of letter to WIPO requesting transfer of rights							

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

JC14 Rec'd PCT/PTO 23 MAR 2005

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION	NO. (if knowr	ATTORNEY'S DOCKET NUMBER							
	by assign	8U 0	PCT/DE200)3/ 03165 45/	2376.0010000)/SRL/TAC			
The followi	ng fees have b	CALCULATIONS	PTO USE ONLY						
21. 💢 Basic n	21. X Basic national fee\$300				\$ 300.00	1			
22. X Examina If International prelii PCT Article 33(1) All other situations.	minary examina -(4)	\$ 200.00							
23. X Search Search fee (37 CFR International International Search All other situations	1,445(a)(2)) has Searching Aut Report prepar	\$ 500.00							
то	TAL OF 21, 22	\$ 1.000.00							
Additional fee for sequence listing. The fee is \$250	r specification g or computer	1.000.00							
Total Sheets	Extra Sheets		additional 50 or fraction up to a whole number)	RATE					
47-100=	/50 =			x \$250	\$				
Surcharge of \$130.0 claimed priority date		\$							
CLAIMS	NUMB	ER FILED	NUMBER EXTRA	RATE	\$	•			
Total claims		- 20 =		x \$50	\$				
Independent claims		- 3 =		x \$200	\$	1			
MULTIPLE DEPEN	ENT CLAIM(S	6) (if applicable)		+ \$360	\$	1			
			TOTAL OF ABOVE	CALCULATIONS =	\$				
Applicant claims	small entity st	atus. See 37 CFR	1.27. Fees above are redu	ced by 1/2.		1			
				SUBTOTAL =	\$ 1,000.00				
Processing fee of \$1 claimed priority date		\$							
_		\$ 1,000.00							
Fee for recording the by an appropriate co		\$							
		* *****	TOTAL F	EES ENCLOSED =	\$ 1,000.00	 			
		Amount to be refunded:	\$						
					Amount to be charged:	\$			
a. A check in the amount of \$ to cover the above fees is enclosed.									
b. Please charge my Deposit Account No in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.									
c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0036 . A duplicate copy of this sheet is enclosed.									
d. X Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not									
be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.									
SEND ALL CORRES		(1/21.00.							
CUSTOMER	NUMBER		<u> </u>						
Sterne, Kessler	, Goldstein	Ceresa A. Colella							
					51,575				

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MENNE et al.

Appl. No.: To be assigned (U.S. Nat'l Phase of

PCT/DE2003/003165)

Filed: Herewith (I.A. Filing Date: September 23,

2003)

For: Inhibition of Protein Kinase C Alpha for Treatment of Diabetes Mellitus and

Cardiovascular Diseases

Confirmation No.: To be assigned

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 2376.0010000/SRL/TAC

Authorization to Treat a Reply as Incorporating an Extension of Time Under 37 C.F.R. § 1.136(a)(3)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Teresa A. Colella
Agent for Applicants

Registration No. 51,575
Date: March 23, 2004

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

377590-1